The migraine
market is saturated with generic drugs, and the remaining branded products
already on the market are expected to lose exclusivity during the next few
years, with the exception of Botox for chronic migraine, which is expected to
maintain its leading position in terms of sales.
However,
reformulations of mature products as well as new classes of therapies are
anticipated to launch during the forecast period and these will contribute to
the market growth. By 2023, the migraine market will grow to $3.7 billion at a
compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate
the market as a result of higher drug prices and a large migraine population.
Access This Full Report @ http://www.radiantinsights.com/research/anti-epileptics-migraine-forecast-and-market-analysis-to-2023
Some of the
new treatments are expected to target the key unmet needs but opportunities
will remain for further treatment choices especially drugs that will offer an
improved safety and side-effects profile.
Anti-epileptics
were originally developed as treatments for epileptic seizures; however, due to
the well-conducted placebo-controlled trials for migraine, they have
demonstrated efficacy in the prophylaxis of migraine, with Depakene (valproic
acid) and Topamax (topiramate) securing FDA approval for the prophylactic
treatment of migraines.
Scope
- Overview
of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive landscape.
- Detailed
information on Anti-epileptics including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales
forecast for Anti-epileptics for the top seven countries from 2012 to 2023.
- Sales
information covered for the US, France, Germany, Italy, Spain, the UK and
Japan.
Reasons to buy
- Understand
and capitalize by identifying products that are most likely to ensure a robust
return
- Stay ahead
of the competition by understanding the changing competitive landscape for
Migraine
-
Effectively plan your M&A and partnership strategies by identifying drugs
with the most promising sales potential
- Make more
informed business decisions from insightful and in-depth analysis of
Anti-epileptics performance
- Obtain
sales forecast for Anti-epileptics from 2012-2023 in the top seven countries
(the US, France, Germany, Italy, Spain, the UK and Japan)
About Us
Radiant Insights is a platform for companies
looking to meet their market research and business intelligence requirements.
We assist and facilitate organizations and individuals procure market research
reports, helping them in the decision making process. We have a comprehensive
collection of reports, covering over 40 key industries and a host of micro
markets. In addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For more
information visit: Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog
URL: http://www.esorics2010.org/
No comments:
Post a Comment